On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


MCTC Holdings Inc. (MCTC) Advances Cannabinoid Delivery Research Efforts, Files Fourth High-Tech Patent

  • Most significant patent filed is also the most comprehensive, covering broad areas of cannabinoid polymeric nanoparticles and fibers
  • Company is committed to continuing research program and expand its intellectual property portfolio over the coming months
  • MCTC participating in multiple growing verticals within global cannabis industry through acquisitions, strategic partnerships, and intellectual property

MCTC Holdings Inc. (OTC: MCTC), a cannabinoid science innovator focused on high-growth and high-margins sub-sectors of the cannabis and hemp industry, filed its fourth cannabinoid delivery technology patent. The patent broadly covers many aspects of nanoparticles and nano fibers comprising one or more cannabinoids disposed at least partially within a water-soluble medium, the company announced in a press release (http://ibn.fm/bCTyI).

MCTC’s R&D program continues with research into development of improved methods to give living systems access to cannabinoids. A key component of the research program is the development of novel polymeric nanofibers and nanoparticles, which have very high potential to significantly improve bioavailability, while allowing for tunability of cannabinoid combinations, ultra-high loading rates, precise dosing, and controlled release parameters at the same time.

According to CEO Arman Tabatabaei, this is the most significant patent the company has filed. “It is by far the most comprehensive covering broad areas of cannabinoid polymeric nanoparticles and fibers. The claims not only cover a plurality of particles within at least a partially water-soluble carrier, but also the process utilizing the precursor mixtures. Not only are nanoparticles and nanofibers included, but also particles below 1.5 microns,” Tabatabaei explained.

The company filed three other patents related to cannabinoid delivery systems in recent months. The first patent, which was on an edible dissolvable film for the delivery of cannabinoids, was the product of collaboration between MCTC and Cannabis Nanosciences, Inc. The companies also cooperated on the second patent, filed on cannabinoid nanoparticles combining TPGS, a water-soluble form of vitamin E. TPGS is a proven and safe bioenhancer of cannabinoids and other hydrophobic compounds. MCTC’s third patent was for a unique 3D printed, 4-dimensional, shape-changing cannabinoid delivery system for beverages.

“We expect to continue to expand our intellectual property portfolio over the coming weeks and months as our research and development programs continue. We believe the area of cannabinoid delivery systems is one of the most exciting areas of the growing cannabinoid sciences arena,” Tabatabaei added.

Currently pending a name change to Cannabis Global, Inc., MCTC Holdings is an integrated cannabis business operation focused on multiple verticals within the fast-growing cannabis and hemp industries via acquisitions, partnerships and intellectual property. An innovator in the field of cannabinoid nanoparticles and infusion technologies, the company concentrates its efforts on the middle part of the industry’s value chain, characterized by high margins and high growth. Its advanced cannabinoid delivery system research can revolutionize the science of cannabinoid bio-enhancement for use in foods, beverages, consumer products and transdermal applications, with the potential for exponential growth in the industry.

For more information, visit the company’s website at www.CannabisGlobalInc.com

NOTE TO INVESTORS: The latest news and updates relating to MCTC are available in the company’s newsroom at http://ibn.fm/MCTC

Last Tweets

Follow us: @Buy_Stocks_Now

From Our Blog

Predictive Oncology Inc. (NASDAQ: POAI) Key Player in AI Implementation in Ovarian Cancer Detection

December 12, 2019

POAI subsidiary sequencing ovarian cancers as part of CancerQuest 2020 project, building largest ovarian multi-omic database in the world Company’s work designed to speed development of new drugs, provide therapeutic choices Helomics recently signed collaborative agreement with UPMC-Magee to establish data- and artificial-intelligence-driven approach to treating ovarian cancer The power of artificial intelligence (AI) to […]

Rotate your device 90° to view site.